Found 16 matching trials
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
PHASE1This research study is studying the drugs called NeoVax (a new type of pers...
Status
Active Not Recruiting
Location
Dana-Farber Cancer Institute
Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
PHASE2The central hypothesis is that the addition of CDX-301 to CDX-1140 radicall...
Location
Washington University School of Medicine
FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
PHASE1The purpose of this study is to test a new way of treating the most common ...
Location
Albert Einstein College of Medicine
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
PHASE1This research study is being done to find out if the immunotherapy drugs ca...
Location
University of Chicago Comprehensive Cancer Center
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
PHASE1This study is designed to evaluate multiple clinical hypotheses and mechani...
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
PHASE1This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 ...
Location
HonorHealth Research Insititute
FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
PHASE2Based on promising data from our laboratory demonstrating synergy between a...
Location
Montefiore Medical Center
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
PHASE1This phase I trial evaluates the safety and effectiveness of in situ immuno...
Status
Active Not Recruiting
Location
Los Angeles General Medical Center
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
PHASE2This phase II trial studies the effect of a vaccine called CDX-1401 given w...
Location
University of Chicago Comprehensive Cancer Center
In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
PHASE1Our recent trials combining local radiotherapy with intratumoral administra...
Location
Icahn School of Medicine at Mount Sinai